Cavanaugh Sarah 4
4 · Celldex Therapeutics, Inc. · Filed Dec 10, 2021
Insider Transaction Report
Form 4
Cavanaugh Sarah
SVP OF CORP AFFAIRS & ADMIN.
Transactions
- Exercise/Conversion
Common Stock
2021-12-08$10.38/sh+5,466$56,737→ 7,731 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2021-12-08−1,857→ 11,458 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (1,857 underlying) - Exercise/Conversion
Common Stock
2021-12-08$9.02/sh+1,857$16,744→ 2,265 total - Sale
Common Stock
2021-12-08$40.00/sh−7,323$292,920→ 408 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2021-12-08−5,466→ 78,534 totalExercise: $10.38Exp: 2030-06-18→ Common Stock (5,466 underlying)
Footnotes (3)
- [F1]The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
- [F2]25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- [F3]25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.